Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 8:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–16 of 16 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Parkinson Disease With Orthostatic Hypotension Clear all
Terminated Phase 3 Interventional Results available

Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure

NCT04095793
View directory record Official record
Conditions
Symptomatic Neurogenic Orthostatic Hypotension
Interventions
ampreloxetine
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
30 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
13
States / cities
Colorado Springs, Colorado • Boca Raton, Florida • Port Charlotte, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2022 · Synced Jul 23, 2026, 8:14 PM EDT
Not listed Phase 2 Interventional

Effect of L-Dihydroxyphenylserine (L-DOPS) on Falls in Patients With Neurogenic Orthostatic Hypotension (NOH)

NCT03567447
View directory record Official record
Conditions
Parkinson Disease, Falls Patient
Interventions
Droxidopa, Placebo
Drug · Other
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
30 Years to 83 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 28, 2019 · Synced Jul 23, 2026, 8:14 PM EDT
Completed Phase 3 Interventional Results available

A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa

NCT00782340
View directory record Official record
Conditions
Symptomatic Neurogenic Orthostatic Hypotension (NOH), Non-diabetic Neuropathy, Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency
Interventions
Placebo, Droxidopa
Drug
Lead sponsor
Chelsea Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
14
States / cities
Huntsville, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 11 more
Source: ClinicalTrials.gov public record
Updated May 15, 2014 · Synced Jul 23, 2026, 8:14 PM EDT
Completed Phase 4 Interventional

Brain Perfusion & Oxygenation in Parkinson's Disease With NOH

NCT03229174
View directory record Official record
Conditions
Parkinson Disease, Neurogenic Orthostatic Hypotension
Interventions
Droxidopa, Placebo
Drug
Lead sponsor
William Ondo, MD
Other
Eligibility
18 Years to 85 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 5, 2022 · Synced Jul 23, 2026, 8:14 PM EDT
Recruiting No phase listed Observational

Natural History Study of Synucleinopathies

NCT01799915
View directory record Official record
Conditions
Patients With Synucleinopathies, Neurogenic Orthostatic Hypotension, Pure Autonomic Failure, REM Sleep Behavior Disorder, Parkinson Disease, Dementia With Lewy Bodies, Multiple System Atrophy, Shy-Drager Disease
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
5
States / cities
Boston, Massachusetts • Ann Arbor, Michigan • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Jul 23, 2026, 8:14 PM EDT
Completed Phase 4 Interventional Results available

Lundbeck TOMs Orthostatic Hypotension

NCT04510922
View directory record Official record
Conditions
Orthostatic Hypotension, Idiopathic Parkinson Disease
Interventions
Droxidopa 100 MG [Northera]
Drug
Lead sponsor
Alberto Espay, MD, MSc
Other
Eligibility
30 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 25, 2022 · Synced Jul 23, 2026, 8:14 PM EDT
Completed Phase 3 Interventional Results available

A Two Part Study (306A/306B) to Assess Droxidopa in Treatment of NOH in Patients With Parkinson's Disease

NCT01176240
View directory record Official record
Conditions
Orthostatic Hypotension, Parkinson's Disease
Interventions
Droxidopa, Placebo
Drug · Other
Lead sponsor
Chelsea Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
60
States / cities
Alabaster, Alabama • Gilbert, Arizona • Phoenix, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Jul 23, 2026, 8:14 PM EDT
Terminated Phase 3 Interventional Results available

A Clinical Study of Patients With Symptomatic NOH to Assess Sustained Effects of Droxidopa Therapy

NCT01927055
View directory record Official record
Conditions
Symptomatic Neurogenic Orthostatic Hypotension, Parkinson's Disease, Multiple Systems Atrophy, Pure Autonomic Failure, Dopamine Beta Hydroxylase Deficiency
Interventions
Droxidopa, Placebo
Drug
Lead sponsor
Chelsea Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
3
States / cities
New York, New York • Charlotte, North Carolina • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 7, 2016 · Synced Jul 23, 2026, 8:14 PM EDT
Completed Phase 3 Interventional Results available

Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure

NCT03750552
View directory record Official record
Conditions
Symptomatic Neurogenic Orthostatic Hypotension
Interventions
ampreloxetine, Placebo
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
30 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
23
States / cities
Sun City, Arizona • Long Beach, California • Palo Alto, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2022 · Synced Jul 23, 2026, 8:14 PM EDT
Completed Phase 4 Interventional Results available

Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension

NCT02586623
View directory record Official record
Conditions
Symptomatic Neurogenic Orthostatic Hypotension
Interventions
Droxidopa capsules, Placebo capsules
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years and older
Enrollment
453 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
168
States / cities
Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 103 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2023 · Synced Jul 23, 2026, 8:14 PM EDT
Completed Early Phase 1 Interventional

Effect of Verdiperstat on Microglial Activation in Well-characterized MSA Patients

NCT04616456
View directory record Official record
Conditions
Multiple System Atrophy, Multiple System Atrophy, Cerebellar Variant, Multiple System Atrophy, Parkinson Variant (Disorder), Multiple System Atrophy (MSA) With Orthostatic Hypotension
Interventions
[F-18]PBR06, Verdiperstat
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 18, 2022 · Synced Jul 23, 2026, 8:14 PM EDT
Completed Phase 2 Interventional Results available

TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH)

NCT02705755
View directory record Official record
Conditions
Neurogenic Orthostatic Hypotension, Multiple System Atrophy (MSA) With Orthostatic Hypotension, Pure Autonomic Failure, Parkinson Disease, Hypotension, Orthostatic, Orthostatic Hypotension, Pure Autonomic Failure With Orthostatic Hypotension, Parkinson Disease With Orthostatic Hypotension
Interventions
TD-9855, Placebo
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
40 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
6
States / cities
Long Beach, California • Farmington Hills, Michigan • Berlin, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2022 · Synced Jul 23, 2026, 8:14 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Effect of Levodopa on Cardiovascular Autonomic Function in Parkinson's Disease

NCT05487300
View directory record Official record
Conditions
Parkinson Disease, Orthostatic Hypotension
Interventions
Autonomic testing on and off levodopa
Drug
Lead sponsor
University of Utah
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Jul 23, 2026, 8:14 PM EDT
Completed Phase 3 Interventional Results available

Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)

NCT00633880
View directory record Official record
Conditions
Symptomatic Neurogenic Orthostatic Hypotension (NOH), Non-diabetic Neuropathy, Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency
Interventions
Placebo, Droxidopa
Drug
Lead sponsor
Chelsea Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
44
States / cities
Birmingham, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Jul 23, 2026, 8:14 PM EDT
Terminated Phase 3 Interventional Results available

Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure

NCT03829657
View directory record Official record
Conditions
Symptomatic Neurogenic Orthostatic Hypotension, MSA, Parkinson's Disease (PD), Pure Autonomic Failure (PAF)
Interventions
ampreloxetine, Placebo
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
30 Years and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
20
States / cities
Sun City, Arizona • La Jolla, California • Palo Alto, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2023 · Synced Jul 23, 2026, 8:14 PM EDT
Completed Phase 3 Interventional Results available

Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)

NCT00738062
View directory record Official record
Conditions
Neurogenic Orthostatic Hypotension, Non-Diabetic Autonomic Neuropathy, Multiple System Atrophy, Dopamine Beta Hydroxylase Deficiency
Interventions
Droxidopa, Placebo
Drug
Lead sponsor
Chelsea Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
44
States / cities
Birmingham, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated May 15, 2014 · Synced Jul 23, 2026, 8:14 PM EDT